COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04218123
Recruitment Status : Recruiting
First Posted : January 6, 2020
Last Update Posted : February 25, 2020
American Hearing Research Foundation
Information provided by (Responsible Party):
Habib Rizk,MD, Medical University of South Carolina

Brief Summary:
As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack of high level evidence for treatments, we seek to perform a randomized, placebo-controlled, double-blind, crossover, pilot trial of venlafaxine for treating Meniere's disease. Venlafaxine is a safe and well-tolerated medication. It has never been trialed in Meniere's disease, but there is evidence that it could be effective in helping with vertigo attacks and other aspects of the disorder.

Condition or disease Intervention/treatment Phase
Meniere Disease Drug: Venlafaxine Drug: Placebo oral tablet Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Actual Study Start Date : February 5, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : March 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Venlafaxine Arm Drug: Venlafaxine
Daily oral intake 37.5 mg

Placebo Comparator: Placebo Drug: Placebo oral tablet
Daily oral intake

Primary Outcome Measures :
  1. Change in Score on Dizziness Handicap Inventory (DHI) [ Time Frame: Baseline to end of treatment (6 months) ]
    The Dizziness Handicap Inventory is a 25-item questionnaire of self-perceived handicap from dizziness.There are 7 questions in the physical domain, 9 in the emotional domain, and 8 in the functional domain. It is scored from 0 (no perceived disability) to 100 (maximum perceived disability).

  2. Change in Score on Neuropsychological Vertigo Inventory (NVI) [ Time Frame: Baseline to end of treatment (6 months) ]
    The English version of the Neuropsychological Vertigo Inventory consists of 28-items with a 5-point Likert scale for each question. It is a cognitive assessment specific to patients with dizziness. The NVI assesses 7 domains of cognition: space perception, attention, time perception, memory, emotional, visual/ocular and motor. The score ranges from 0 to 140. The higher the score on the NVI the worse the cognitive function of the subject.

  3. Change in Score on Cognitive Failure Questionnaire (CFQ) [ Time Frame: Baseline to end of treatment (6 months) ]
    The Cognitive Failure Questionnaire is a 25-item survey which assesses cognitive and executive function not tied to any specific disease state. It aims to assess perception, memory, and motor function in everyday tasks.The score ranges from 0 to 100 The higher score on the CFQ, the more frequent the cognitive failures experienced by the subject

  4. Change in Score on Patient Health Questionnaire (PHQ9) [ Time Frame: Baseline to end of treatment (6 months) ]
    The Patient Health Questionnaire is a 9-item survey which assesses the severity of depression. A low score is indicative of little to no depressive symptoms, and a high score is indicative of Moderately severe to severe depressive symptoms. Scores range from 0 to 27 with scores higher than 20 indicative of significant risk for depression and scores below 10 indicative at most of a mild depression.

  5. Change in Score on Penn State Worry Questionnaire (PSWQ) [ Time Frame: Baseline to end of treatment (6 months) ]
    The PSWQ is a 16-item survey for assessment of anxiety which has been used to identify generalized anxiety disorder. Scores range from 16 (Low worry) to 80 (high worry). A score higher than 60 is indicative of significant anxiety and risk for an anxiety disorder

  6. Change in Score on The Meniere's Disease Patient-Oriented Symptom Index (MDPOSI) [ Time Frame: Baseline to end of treatment (6 months) ]
    The Meniere's Disease Patient-Oriented Symptom Index is a 23-item survey developed as a MD-specific tool to assess the impact of MD symptoms on patients' lives. The score ranges from 0 to 100 with the higher score indicating an active disease with significant impact on function and quality of life.

  7. Change in Score on The Medical Outcomes Study 20-item Short Form Health Survey [ Time Frame: Baseline to end of treatment (6 months) ]
    The Medical Outcomes Study 20-item Short Form Health Survey is a 20-item general health questionnaire to assess quality of life in chronic diseases. It assesses 6 areas of health: physical functioning, role functioning, social functioning, mental health, health perceptions, and pain. Scores range between 0 and 100, with 100 indicating best possible function and 0 the worst possible function

  8. Number of Vertigo Episodes [ Time Frame: 6 months ]
    Patients will be keeping a diary throughout the study period and beyond.

  9. Severity of Vertigo [ Time Frame: 6 months ]

    The study team will use a modified version of vertigo control classification because the treatment phases are 2 months long and the study team will not be able to wait 18-24 months after treatment to assess efficacy per academy guidelines. Previous studies have defined four categories of response to treatment: 1) very good response if more than 75% reduction in vertigo spells frequency and/or intensity, 2) good response if 50-75% reduction, 3) fair response if 25-50% reduction, and 4) poor response if less than 25% reduction.

    The vertigo classes will be defined as follows; Class A: 0 (complete control of vertigo) Class B: 0-40 or >60% reduction in mean vertigo episode severity (good control of vertigo) Class C: 41-80 or 20-60% reduction in severity (fair control of vertigo) Class D: 81-120 or -20-20% reduction in severity (no change in vertigo) Class E: >120 or >20% worsening in severity (worse vertigo)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Study subjects will be prospectively recruited from the population of patients presenting with dizziness to our tertiary, multidisciplinary, vestibular-focused, neurotology clinic. Subjects must meet the following inclusion criteria:

  • be 18 years of age or older;
  • have definite MD as defined by the Barany Society 2015 international consensus statement;
  • have active MD with at least 2 vertigo episodes in the month prior to enrollment; and score at least 36 on the Dizziness Handicap Inventory (DHI), representing at least moderate handicap.

Patients with the following will be excluded:

  • other concurrent vestibular or balance disorder (especially those with vestibular migraine-related vertigo episodes despite not meeting diagnostic criteria for vestibular migraine);
  • currently taking venlafaxine, SSRIs, or SNRIs;
  • history of medical (e.g. gentamicin) or surgical (e.g. labyrinthectomy) vestibular ablative treatment;
  • history of otologic, lateral skull base, or brain surgery;
  • history of radiation to the head or neck;
  • known neurologic disorder affecting cognition;
  • currently taking another serotonin modulating medication;
  • seizures;
  • stroke;
  • myocardial infarction;
  • hepatic or renal impairment;
  • hyperlipidemia;
  • coagulopathy;
  • psychiatric disorder other than anxiety or depression;
  • glaucoma;
  • uncontrolled hypertension;
  • pregnancy or intention of pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04218123

Layout table for location contacts
Contact: Habib Rizk, MD 843-876-0112
Contact: Yuan Liu, MD 843-834-5077

Layout table for location information
United States, South Carolina
Medical Univeristy of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
American Hearing Research Foundation
Layout table for investigator information
Principal Investigator: Habib Rizk, MD Medical University of South Carolina
Layout table for additonal information
Responsible Party: Habib Rizk,MD, Assistant Professor, Medical University of South Carolina Identifier: NCT04218123    
Other Study ID Numbers: 00091200
First Posted: January 6, 2020    Key Record Dates
Last Update Posted: February 25, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Meniere Disease
Endolymphatic Hydrops
Labyrinth Diseases
Ear Diseases
Otorhinolaryngologic Diseases
Venlafaxine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs